Microchip Capillary Electrophoresis Assays and Reagents Faster Quality Checks for Antibody Drugs

This patent describes assays and reagents that run capillary electrophoresis on a microchip to analyse protein drugs such as antibodies. It comes from Regeneron Pharmaceuticals, Inc., an American biotechnology company.

The Problem

Antibody medicines are large, complex proteins, and before a batch can be used it must be checked in fine detail: how pure it is, whether the protein has fragmented or clumped, and whether its structure matches the intended design. Electrophoresis, which separates molecules by pushing them through a medium with an electric field, is a standard tool for these checks, but traditional formats can be slow, use large amounts of sample and reagent, and be hard to run consistently. Drug developers need separation methods that are faster, use tiny sample volumes, and give reproducible, high-resolution results so quality can be confirmed reliably across many batches.

What This Invention Does

The patent describes microchip capillary electrophoresis assays together with the reagents they use. Instead of a conventional capillary, the separation runs in tiny channels etched into a microchip, so each analysis needs only a very small amount of sample and reagent and completes quickly. The filing sets out the reagent formulations and assay conditions that give clean, repeatable separations of antibodies and related proteins, letting analysts measure purity, detect fragments or aggregates, and characterise the molecule. The IPC classifications point to antibody subject matter combined with protein analysis methods. By defining both the on-chip assay and the reagents that make it work, the invention aims at fast, reproducible, low-volume quality analysis suited to developing and manufacturing protein drugs.

Key Features

• On-chip separation. The electrophoresis runs in microchannels on a chip rather than a conventional capillary.
• Small volumes. Each assay uses only tiny amounts of sample and reagent.
• Defined reagents. Specific reagent formulations give clean, repeatable separations.
• Protein characterisation. The assays measure purity and detect fragments or aggregates in antibody products.
• Reproducible results. Set assay conditions support consistent analysis across many batches.

Who Is Behind It

The applicant is Regeneron Pharmaceuticals, Inc., a Tarrytown, New York biotechnology company known for developing antibody-based medicines. The named inventors are Timothy Riehlman, Gabriel Carreau, Jeffrey Schneiderheinze, and Nicole M. Nall. This filing is a divisional application from an earlier related Australian application.

Why It Matters

Analytical methods rarely make headlines, but they are the backbone of safe biologic medicines: every batch has to be proven pure and correctly structured before it reaches patients. Faster, lower-volume, reproducible separation assays speed development and tighten quality control across manufacturing. Protecting these assays and reagents in Australia supports the company’s analytical and manufacturing work in the region.

Related Concepts

• Capillary electrophoresis – the separation technique this invention runs on a chip.
• Electrophoresis – the general method of separating molecules with an electric field.
• Antibody – the class of protein drug these assays analyse.
• Lab-on-a-chip – the miniaturised analysis approach the microchip embodies.
• Analytical chemistry – the field concerned with measuring composition and purity.

---

AU 2026201984 was published in the Australian Official Journal of Patents on 2 April 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.